These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37788264)

  • 21. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
    Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
    Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
    BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Queiroz NSF; Saad-Hossne R; FrÓes RSB; Penna FGCE; Gabriel SB; Martins AL; Teixeira FV
    Arq Gastroenterol; 2020; 57(3):232-243. PubMed ID: 32935741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States.
    Teeple A; Ginsburg S; Howard L; Huff L; Reynolds C; Walls D; Ellis LA; Curtis JR
    Curr Med Res Opin; 2019 Apr; 35(4):603-609. PubMed ID: 30618353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
    Wiland P; Jeka S; Dokoupilová E; Brandt-Jürgens J; Miranda Limón JM; Cantalejo Moreira M; Cabello RV; Jauch-Lembach J; Thakur A; Haliduola H; Brueckmann I; Gaylis NB
    BioDrugs; 2020 Dec; 34(6):809-823. PubMed ID: 33119861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.
    Desai RJ; Kim SC; Curtis JR; Bosco JLF; Eichelberger B; Barr CE; Lockhart CM; Bradbury BD; Clewell J; Cohen HP; Gagne JJ;
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):757-769. PubMed ID: 31298463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.
    Bloomfield D; D'Andrea E; Nagar S; Kesselheim A
    JAMA Oncol; 2022 Apr; 8(4):537-545. PubMed ID: 35113135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of switching between rituximab biosimilars in onco-hematology.
    Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
    Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
    Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
    J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
    Hung A; Vu Q; Mostovoy L
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.
    Inotai A; Prins CPJ; Csanádi M; Vitezic D; Codreanu C; Kaló Z
    Expert Opin Biol Ther; 2017 Aug; 17(8):915-926. PubMed ID: 28650704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
    Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
    JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
    Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
    Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.
    Moots R; Azevedo V; Coindreau JL; Dörner T; Mahgoub E; Mysler E; Scheinberg M; Marshall L
    Curr Rheumatol Rep; 2017 Jun; 19(6):37. PubMed ID: 28623625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.